People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Pharma, Biotechnology, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pyxis Oncology, Inc. | — | Pharma | Series D+ | $194.5M | $5.0B | 2019 |
| OncoResponse Inc | — | Biotechnology | Series C | $109.0M | $39.4M | 2015 |
| Carbon Biosciences, Inc. | — | Biotech / Pharma | Series B | $38.0M | $744.8M | 2022 |
| Syntimmune, Inc. | — | Biotechnology | Series B | $26.0M | $714.4M | 2014 |
| Corridor Pharmaceuticals, Inc. | — | Biotechnology | Series A | $18.7M | $56.3M | 2009 |
| ViTToria Biotherapeutics, Inc. | — | Biotechnology | Series A | $8.7M | $188.2M | 2021 |
| Cantai Therapeutics, Inc. | — | Biotechnology | Seed | $4.3M | $6.2M | 2023 |
Geeta Vemuri at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Geeta Vemuri on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Steinberg | 2 | 14 |
| Steven Gillis | 1 | 23 |
| Seth Harrison | 1 | 19 |
| Wende Hutton | 1 | 16 |
| Andrew Perlman | 1 | 15 |
| Steve Gillis | 1 | 13 |
| Errik Anderson | 1 | 8 |
| Christoph Westphal | 1 | 8 |
| Christopher O'Donnell | 1 | 8 |
| Robert Crane | 1 | 7 |
| John McKearn | 1 | 6 |
| Lucio Iannone | 1 | 6 |
| Aaron Kantoff | 1 | 6 |
| Errik B. Anderson | 1 | 5 |
| Bruce Peacock | 1 | 5 |
| Clifford Stocks | 1 | 5 |
| John Flavin | 1 | 4 |
| Chen Schor | 1 | 4 |
| Jak Knowles | 1 | 4 |
| TED KOUTOUZIS | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.